TABLE 6.
Influence of PTX3 SNPs on the risk of invasive candidiasis in high-risk oncohematology patientsa
| SNP | Model | Genotype | No. (%) of patients with candidiasis |
No. (%) of patients without candidiasis |
OR (95% CI) | P value | BIC |
|---|---|---|---|---|---|---|---|
| rs2305619 | Codominant | AA | 4 (36.4) | 37 (19.8) | 1.00 | ||
| AG | 6 (54.5) | 98 (52.4) | 1.94 (0.5–7.58) | 0.18 | 137 | ||
| GG | 1 (9.1) | 52 (27.8) | 6.66 (0.69–64.0) | ||||
| Dominant | AA | 4 (36.4) | 37 (19.8) | 1.00 | |||
| AG+GG | 7 (63.6) | 150 (80.2) | 2.62 (0.7–9.8) | 0.17 | 133.3 | ||
| Recessive | AA+AG | 10 (90.9) | 135 (72.2) | 1.00 | |||
| GG | 1 (9.1) | 52 (27.8) | 4.26 (0.5–34.66) | 0.11 | 132.6 | ||
| rs3816527 | Codominant | CC | 2 (18.2) | 32 (17.1) | 1.00 | ||
| CA | 7 (63.6) | 94 (50.3) | 0.87 (0.16–4.65) | 0.45 | 138.9 | ||
| AA | 2 (18.2) | 61 (32.6) | 2.3 (0.3–17.85) | ||||
| Dominant | CC | 2 (18.2) | 32 (17.1) | 1.00 | |||
| CA+AA | 9 (81.8) | 155 (82.9) | 1.19 (0.24–6.04) | 0.83 | 135.1 | ||
| Recessive | CC+CA | 9 (81.8) | 126 (67.4) | 1.00 | |||
| AA | 2 (18.2) | 61 (32.6) | 2.55 (0.52–12.5) | 0.21 | 133.6 | ||
| rs1840680 | Codominant | AA | 5 (45.5) | 37 (19.8) | 1.00 | ||
| AG | 5 (45.5) | 95 (50.8) | 2.75 (0.73–10.4) | 0.07 | 135.1 | ||
| GG | 1 (9.1) | 55 (29.4) | 9.12 (0.99–84.3) | ||||
| Dominant | AA | 5 (45.5) | 37 (19.8) | 1.00 | |||
| AG+GG | 6 (54.5) | 150 (80.2) | 3.8 (1.05–13.57) | 0.048 | 131.3 | ||
| Recessive | AA+AG | 10 (90.9) | 132 (70.6) | 1.00 | |||
| GG | 1 (9.1) | 55 (29.4) | 4.8 (0.59–39.22) | 0.076 | 132 | ||
a
Association analysis for the risk of invasive candidiasis in 198 patients. The study, adjusted for sex, age, and hematological malignancy, showed a significant association for SNP rs1840680. The significant associations at a P value of <0.05 are indicated in boldface type.